Celularity Celularity
  • Home
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Manufacturing
    • Biobanking
    • Tour Our Facility
    • Expanded Access Policy
  • Science
    • Power of Placenta
    • NK Cell Platform
    • T Cell Platform
    • Exosomes
    • Advanced Biomaterials
  • Pipeline
  • Newsroom
  • Investors
    • Investor Relations
    • SEC Filings
    • Corporate Governance
  • Careers
Celularity
MENU
December 6, 2024

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

...
November 7, 2024

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

...
October 23, 2024

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

...
October 22, 2024

Celularity Provides Corporate Update

...
October 16, 2024

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

...
September 5, 2024

Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference

...
August 28, 2024

Celularity Appoints Richard J. Berman to its Board of Directors

...
July 31, 2024

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

...
June 3, 2024

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

...
May 14, 2024

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

...
April 22, 2024

Celularity Inc. to Host Investor and Analyst Research & Development Day

...
April 18, 2024

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

...
April 15, 2024

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

...
April 8, 2024

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

...
March 26, 2024

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

...
March 20, 2024

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

...
March 14, 2024

Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit

...
March 12, 2024

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

...
March 7, 2024

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

...
February 23, 2024

Celularity Announces 1-for-10 Reverse Stock Split

...
12
Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Company

  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers

Science

  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing

Investors

  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2025. All rights reserved.     Privacy Policy     Terms & Conditions

Company
  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers
Science
  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing
Investors
  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy     Terms & Conditions